![[시그널] SK Bioscience’s demand forecast is close to 1,000:1… Will general subscriptions be jackpots?](https://newsimg.sedaily.com/2021/03/05/22JOW18AA7_4.jpg "[시그널] SK Bioscience’s demand forecast is close to 1,000:1… Will general subscriptions be jackpots?")
On the 5th, finishing the demand forecast for institutions
Enter KOSPI after regular subscription for 9-10 days
Listing organizer NH Investment & Securities
viewer
SK Bioscience, one of the biggest IPOs in the first half of the year, succeeded in making a hit in forecasting demand for institutional investors. Among companies with a corporate value of over 5 trillion won, the competition rate is exceptionally close to 1,000:1, and it is interesting whether the feverish demand forecast will lead to a general subscription box office. It is reported that a large number of foreign investors, such as Singapore Investment Agency (GIC), also participated in the subscription, while domestic institutions are proposing a commitment to retain the obligation to receive more public offering stocks for even one week.
According to the investment banking (IB) industry on the 5th, SK Bioscience’s demand forecast competition rate was close to 1,000:1. It is known that the percentage of the company committed to holding the stock for a certain period is also around 60%. Demand forecasting is a step in which the public offering price, etc., is determined prior to subscription to general investors. With the competition rate approaching 1,000:1, it is evaluated that it exceeded the public offering fever of SK Biopharm, which drove the public offering stock craze last year. SK Biopharm recorded a competition rate of 836 to 1 in the demand forecast for institutions in August of last year, and raised a margin of 31 trillion won in general subscription.
SK Biosciences is a vaccine company that has recently attracted attention for its production and development of a novel coronavirus infection (Corona 19) vaccine. It is also true that some companies were controversial over valuation of corporate value while promoting listing with a corporate value of about 5 trillion won. However, the investment sentiment of the institutions was hot. In the case of domestic institutions, it is known that they have confirmed their participation in demand forecasting and have proposed a commitment to retain the obligation to receive one more share of the public offering, and foreign institutional investors such as GIC and the Norwegian Bank have also joined the ranks to receive publicly offered shares.
It seems that the company’s value has recently soared due to the production of the Corona 19 vaccine, and the low distribution ratio of public offering stocks as of the day of listing is at the level of 20%. Demand forecasts for institutions are successful, and interest is focused on whether general investor subscriptions will also be successful.
After forecasting demand, SK Bioscience plans to complete the listing process on the 18th after completing the subscription for general investors on the 9th to 10th. General subscription is the representative organizer NH Investment & Securities (005940)It is carried out through Korea Investment & Securities co-organizers, Mirae Asset Daewoo acquisition group SK Securities, Hana Financial Investment, and Samsung Securities.
/ Reporter Minseok Kim [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >